molecules-logo

Journal Browser

Journal Browser

Advanced Analytical Technologies for Anti-cancer Drugs Analysis

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Analytical Chemistry".

Deadline for manuscript submissions: closed (15 December 2021) | Viewed by 2545

Special Issue Editor


E-Mail Website
Guest Editor
Laboratoire de Pharmaco-Toxicologie, Centre de Biologie-Sud, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, F-69495 Pierre Bénite, France
Interests: mass spectrometry; anticancer drugs; HPLC; therapeutic drug monitoring; method validation; monoclonal antibodies in cancer therapy

Special Issue Information

Dear Colleagues,

With the increase in cancer incidence, treatments containing cytotoxic drugs are widely used. The arrival of new selective therapies, such as tyrosine kinase inhibitors or monoclonal antibodies, keeps this therapeutic class very active and very stimulating for researchers. Analytical methods play a major role in the development of knowledge regarding their uses. Given the structural diversity of the drugs used in cancer treatments with chemotherapy and low molecular weight drugs to immunotherapy and monoclonal antibodies, there is a very wide range of analytical approaches. Therefore, it is our pleasure to invite authors to submit an article for a Special Issue of Molecules titled “Advanced Analytical Technologies for Anti-cancer Drugs Analysis”, for which we serve as Guest Editors. This Special Issue aims to cover research trends in the development of analytical and bioanalytical methods that are relevant to the analysis of cytotoxic agents in pharmaceutical formulations, in biological samples (new drugs or new formulations, therapeutic drug monitoring, biomonitoring of exposed healthcare professionals, in environmental samples (surface and air contamination, wastewater)).

This Special Issue will consist of a comprehensive review, original research articles or short communications featuring important and recent developments in the analysis of anticancer drugs, including chemotherapy and monoclonal antibodies. The topics of interest for this Special Issue include, but are not limited to, the following:

  • therapeutic drug monitoring
  • pharmaceutical analysis
  • environmental
  • cell or organ distribution
  • drug metabolism
  • occupational exposure
  • toxicology
  • biochemical analysis
  • mass spectrometry
  • analytical chemistry

Papers on interesting developments related to sample preparation, separation techniques, and spectroscopic methods, as well as any novel techniques for small molecules or monoclonal antibodies, are very welcome.

The submission deadline is 15 December 2021. All manuscripts will undergo a comprehensive review according to standard journal procedures and policies.

Prof. Dr. Jérôme Guitton
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • therapeutic drug monitoring
  • pharmaceutical analysis
  • environmental
  • cell or organ distribution
  • drug metabolism
  • occupational exposure
  • toxicology
  • biochemical analysis
  • mass spectrometry
  • analytical chemistry

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1167 KiB  
Article
High-Throughput Method for the Simultaneous Determination of Doxorubicin Metabolites in Rat Urine after Treatment with Different Drug Nanoformulations
by Lara Zorić, Nikša Drinković, Vedran Micek, Leo Frkanec, Akif Emre Türeli, Nazende Günday-Türeli, Ivana Vinković Vrček and Ruža Frkanec
Molecules 2022, 27(4), 1177; https://doi.org/10.3390/molecules27041177 - 9 Feb 2022
Cited by 2 | Viewed by 2082
Abstract
Doxorubicin (DOX) is one of the most effective cytotoxic agents against malignant diseases. However, the clinical application of DOX is limited, due to dose-related toxicity. The development of DOX nanoformulations that significantly reduce its toxicity and affect the metabolic pathway of the drug [...] Read more.
Doxorubicin (DOX) is one of the most effective cytotoxic agents against malignant diseases. However, the clinical application of DOX is limited, due to dose-related toxicity. The development of DOX nanoformulations that significantly reduce its toxicity and affect the metabolic pathway of the drug requires improved methods for the quantitative determination of DOX metabolites with high specificity and sensitivity. This study aimed to develop a high-throughput method based on high-performance liquid chromatography with fluorescence detection (HPLC-FD) for the quantification of DOX and its metabolites in the urine of laboratory animals after treatment with different DOX nanoformulations. The developed method was validated by examining its specificity and selectivity, linearity, accuracy, precision, limit of detection, and limit of quantification. The DOX and its metabolites, doxorubicinol (DOXol) and doxorubicinone (DOXon), were successfully separated and quantified using idarubicin (IDA) as an internal standard (IS). The linearity was obtained over a concentration range of 0.05–1.6 μg/mL. The lowest limit of detection and limit of quantitation were obtained for DOXon at 5.0 ng/mL and 15.0 ng/mL, respectively. For each level of quality control (QC) samples, the inter- and intra-assay precision was less than 5%. The accuracy was in the range of 95.08–104.69%, indicating acceptable accuracy and precision of the developed method. The method was applied to the quantitative determination of DOX and its metabolites in the urine of rats treated by novel nanoformulated poly(lactic-co-glycolic acid) (DOX-PLGA), and compared with a commercially available DOX solution for injection (DOX-IN) and liposomal-DOX (DOX-MY). Full article
(This article belongs to the Special Issue Advanced Analytical Technologies for Anti-cancer Drugs Analysis)
Show Figures

Graphical abstract

Back to TopTop